PURPOSE: To report the results of a consecutive series of patients who underwent an endoscopic endonasal approach (EEA) for resection of a pituitary adenoma and compare them to previous series of microscopic and endoscopic approaches. METHODS: A retrospective review of clinical and radiographic outcomes of a consecutive series of patients operated at our center between 2002 and 2011 was performed. RESULTS: 555 patients underwent an EEA for removal of a pituitary adenoma. The mean follow up was 3.1 years (range 3 months to 9.5 years); 36 were lost to follow up. Ninety-one (17.5%) harbored recurrent adenomas. An expanded approach to reach the supra-, para- and infra-sellar spaces was employed in 290 patients (55.9%). Reconstruction with a nasal septal flap was used in 238 cases (65.6%). The rate of gross total resection was 65.3% in the 359 patients with non-functioning adenomas. The remission rates with EEA alone were 82.5% in the 57 ACTH-secreting adenomas, 65.3% in the 49 GH-secreting adenomas and 54.7% in the 53 prolactinomas. Of the 237 patients presenting with visual loss, 190 (80.2%) improved or normalized, 41 (17.3%) remained unchanged and 4 (1.7%) experienced transient visual deterioration due to postoperative apoplexy. In addition, no patient without preexisting visual loss suffered new visual decline. The overall post-operative CSF leak rate was 5% and this decreased to 2.9% after the introduction of reconstruction with the naso-septal flap. Two patients (0.3%) had an ICA injury. CONCLUSIONS: The EEA is a safe and effective way to surgically approach pituitary adenomas, particularly in recurrent tumors, those with supra-sellar extension or cavernous sinus invasion. The remission and complication rates are comparable or favorable compared with those reported in previous series of microscopic and endoscopic approaches.
PURPOSE: To report the results of a consecutive series of patients who underwent an endoscopic endonasal approach (EEA) for resection of a pituitary adenoma and compare them to previous series of microscopic and endoscopic approaches. METHODS: A retrospective review of clinical and radiographic outcomes of a consecutive series of patients operated at our center between 2002 and 2011 was performed. RESULTS: 555 patients underwent an EEA for removal of a pituitary adenoma. The mean follow up was 3.1 years (range 3 months to 9.5 years); 36 were lost to follow up. Ninety-one (17.5%) harbored recurrent adenomas. An expanded approach to reach the supra-, para- and infra-sellar spaces was employed in 290 patients (55.9%). Reconstruction with a nasal septal flap was used in 238 cases (65.6%). The rate of gross total resection was 65.3% in the 359 patients with non-functioning adenomas. The remission rates with EEA alone were 82.5% in the 57 ACTH-secreting adenomas, 65.3% in the 49 GH-secreting adenomas and 54.7% in the 53 prolactinomas. Of the 237 patients presenting with visual loss, 190 (80.2%) improved or normalized, 41 (17.3%) remained unchanged and 4 (1.7%) experienced transient visual deterioration due to postoperative apoplexy. In addition, no patient without preexisting visual loss suffered new visual decline. The overall post-operative CSF leak rate was 5% and this decreased to 2.9% after the introduction of reconstruction with the naso-septal flap. Two patients (0.3%) had an ICA injury. CONCLUSIONS: The EEA is a safe and effective way to surgically approach pituitary adenomas, particularly in recurrent tumors, those with supra-sellar extension or cavernous sinus invasion. The remission and complication rates are comparable or favorable compared with those reported in previous series of microscopic and endoscopic approaches.
Authors: Alberto M Pereira; Maarten O van Aken; Hans van Dulken; Pieter J Schutte; Nienke R Biermasz; Jan W A Smit; Ferdinand Roelfsema; Johannes A Romijn Journal: J Clin Endocrinol Metab Date: 2003-12 Impact factor: 5.958
Authors: Gustavo Hadad; Luis Bassagasteguy; Ricardo L Carrau; Juan C Mataza; Amin Kassam; Carl H Snyderman; Arlan Mintz Journal: Laryngoscope Date: 2006-10 Impact factor: 3.325
Authors: Gary D Hammer; J Blake Tyrrell; Kathleen R Lamborn; Carol B Applebury; Elizabeth T Hannegan; Scott Bell; Riva Rahl; Amy Lu; Charles B Wilson Journal: J Clin Endocrinol Metab Date: 2004-12 Impact factor: 5.958
Authors: Karl Lindberg; Angelica Kouti; Doerthe Ziegelitz; Tobias Hallén; Thomas Skoglund; Dan Farahmand Journal: J Neurol Surg B Skull Base Date: 2018-01-19
Authors: Tristan P C van Doormaal; Sander J H Diederen; Albert van der Zwan; Jan Willem Berkelbach; Arvid Kropveld; Paul R A M Depauw Journal: J Neurol Surg B Skull Base Date: 2017-08-23